Table 3.
Adjusted hazard ratios (95 % CI) for incident CVD, CV mortality, and total mortality by age groups: Tehran lipid and glucose study.
| Age <60 years | Age ≥60 years | |||||||
|---|---|---|---|---|---|---|---|---|
| E/N | Model 1 | Model 2 | E/N | Model 1 | Model 2 | Interaction | ||
| HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | HR (95 % CI) | p–value* | ||||
| Incident 1st CVD | ||||||||
| FPG <100 mg/dl | 343/4,627 | Reference | Reference | 222/850 | Reference | Reference | 0.31 | |
| FPG (100–125 mg/dl) | 26/167 | 1.77 (1.39–2.25) | 1.39 (1.09–1.77) | 17/62 | 1.29 (0.98–1.70) | 1.15 (0.87–1.52) | ||
| 2 h–PCG <140 mg/dl | 287/4,137 | Reference | Reference | 171/679 | Reference | Reference | 0.037 | |
| 2 h–PCG (140–199 mg/dl) | 82/657 | 2.01 (1.57–2.58) | 1.53 (1.19–1.97) | 68/233 | 1.21 (0.92–1.61) | 1.03 (0.77–1.36) | ||
| FPG <100 mg/dl or 2 h–PCG < 140 mg/dl | 331/4,538 | Reference | Reference | 204/800 | Reference | Reference | 0.062 | |
| FPG (100–125 mg/dl) and 2 h–PCG (140–199 mg/dl) | 38/256 | 2.24 (1.60–3.13) | 1.60 (1.14–2.25) | 35/112 | 1.21 (0.84–1.73) | 1.00 (0.70–1.43) | ||
| CV mortality | ||||||||
| FPG <100 mg/dl | 30/4,182 | Reference | Reference | 50/773 | Reference | Reference | 0.09 | |
| FPG (100–125 mg/dl) | 10/748 | 1.81 (0.89–3.71) | 1.46 (0.71–3.01) | 12/267 | 0.67 (0.36–1.27) | 0.64 (0.34–1.20) | ||
| 2 h–PCG <140 mg/dl | 32/4,237 | Reference | Reference | 46/772 | Reference | Reference | 0.49 | |
| 2 h–PCG (140–199 mg/dl) | 8/693 | 1.65 (0.76–3.58) | 1.26 (0.57–2.76) | 16/268 | 1.04 (0.59–1.83) | 0.90 (0.50–1.59) | ||
| FPG <100 mg/dl or 2 h–PCG <140 mg/dl | 37/4,657 | Reference | Reference | 59/908 | Reference | Reference | 0.14 | |
| FPG (100–125 mg/dl) and 2 h–PCG (140–199 mg/dl) | 3/273 | 1.46 (0.45–4.74) | 1.00 (0.30–3.27) | 3/132 | 0.34 (0.11–1.01) | 0.29 (0.09–0.93) | ||
| Non–CV mortality | ||||||||
| FPG <100 mg/dl | 64/4,182 | Reference | Reference | 146/773 | Reference | Reference | 0.06 | |
| FPG (100–125 mg/dl) | 21/748 | 1.73 (1.06–2.83) | 1.71 (1.04–2.80) | 49/267 | 0.96 (0.69–1.32) | 0.98 (0.70–1.36) | ||
| 2h–PCG <140 mg/dl | 66/4,237 | Reference | Reference | 140/772 | Reference | Reference | 0.045 | |
| 2 h–PCG (140–199 mg/dl) | 22/693 | 2.10 (1.29–3.41) | 2.12 (1.30–3.46) | 55/268 | 1.18 (0.86–1.61) | 1.17 (0.86–1.61) | ||
| FPG <100 mg/dl or 2h–PCG <140 mg/dl | 80/4,657 | Reference | Reference | 168/908 | Reference | Reference | 0.27 | |
| FPG (100–125 mg/dl) and 2h–PCG (140–199 mg/dl) | 8/273 | 1.76 (0.85–3.65) | 1.72 (0.83–3.59) | 27/132 | 1.08 (0.72–1.63) | 1.08 (0.72–1.63) | ||
| Total mortality | ||||||||
| FPG <100 mg/dl | 97/4,182 | Reference | Reference | 196/773 | Reference | Reference | 0.016 | |
| FPG (100–125 mg/dl) | 31/748 | 1.76 (1.17–2.63) | 1.63 (1.08–2.45) | 61/267 | 0.88 (0.66–1.78) | 0.88 (0.66–1.18) | ||
| 2 h–PCG <140 mg/dl | 98/4,237 | Reference | Reference | 186/772 | Reference | Reference | 0.044 | |
| 2 h–PCG (140–199 mg/dl) | 30/693 | 1.95 (1.29–2.94) | 1.82 (1.20–2.76) | 71/268 | 1.14 (0.87–1.50) | 1.09 (0.83–1.45) | ||
| FPG <100 mg/dl or 2 h–PCG <140 mg/dl | 117/4,657 | Reference | Reference | 227/908 | Reference | Reference | 0.14 | |
| FPG (100–125 mg/dl) and 2 h–PCG (140–199 mg/dl) | 11/273 | 1.67 (0.90–3.09) | 1.47 (0.79–2.75) | 30/132 | 0.89 (0.61–1.30) | 0.85 (0.58–1.25) | ||
FPG, fasting plasma glucose; 2 h–PCG, 2–h post–challenge plasma glucose; HR, hazard ratio; CVD, cardiovascular disease.
Model 1, adjusted for age, and gender; model 2, adjusted for age, gender, body mass index, hypercholesterolemia, hypertension, current smoking, eGFR, prevalent CVD.
Bold values are statistically significant.